Eli Lilly's Weight Loss Pill Success: Eli Lilly announced that its oral weight loss medication, orforglipron, has shown significant efficacy in helping patients with obesity and Type 2 diabetes lose weight in a late-stage trial, paving the way for global approval.
Comparison to Existing Treatments: The pill offers a convenient needle-free alternative to existing GLP-1 injections, with no dietary restrictions, although it has been noted that some patients experienced side effects leading to treatment discontinuation.
Clinical Trial Results: In the study, patients on the highest dose lost an average of 10.5% of their body weight over 72 weeks, and many achieved improved blood sugar levels, with most no longer meeting the criteria for Type 2 diabetes by the end of the trial.
Market Potential and Accessibility: Experts believe that the introduction of an oral option could expand access to obesity treatments, potentially making them more affordable and easier to manufacture compared to current injectable options.
NVO
$48.96+Infinity%1D
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast NVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 57.37 USD with a low forecast of 47.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 50.370
Low
47.00
Averages
57.37
High
70.00
Current: 50.370
Low
47.00
Averages
57.37
High
70.00
HSBC
Hold
maintain
$47 -> $54
2025-12-10
Reason
HSBC
Price Target
$47 -> $54
2025-12-10
maintain
Hold
Reason
HSBC raised the firm's price target on Novo Nordisk to $54 from $47 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."
Argus
Buy -> Hold
downgrade
2025-12-08
Reason
Argus
Price Target
2025-12-08
downgrade
Buy -> Hold
Reason
Argus downgraded Novo Nordisk to Hold from Buy. The company has seen the market share of its GLP-1 drugs - Wegovy and Ozempic - decline in recent quarters and has also agreed to lower prices of these drugs in the U.S. markets, the analyst tells investors in a research note. Novo Nordisk will also soon face the entrance of generic versions of these products in certain international markets while, concurrently, some of the company's key clinical trials have "failed to impress", with the recent trials of semaglutide not confirming superiority relative to placebo in reduction of Alzheimer's disease progression, the firm added.
Argus
Buy
to
Hold
downgrade
2025-12-08
Reason
Argus
Price Target
2025-12-08
downgrade
Buy
to
Hold
Reason
Argus downgraded Novo Nordisk to Hold from Buy.
JPMorgan
Richard Vosser
Overweight
downgrade
2025-12-08
Reason
JPMorgan
Richard Vosser
Price Target
2025-12-08
downgrade
Overweight
Reason
JPMorgan analyst Richard Vosser lowered the firm's price target on Novo Nordisk to DKK 350 from DKK 500 and keeps an Overweight rating on the shares.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
